Galera Therapeutics, Inc.
GRTX
$0.0235
-$0.0004-1.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 67.91% | 71.85% | 58.80% | 29.05% | 5.05% |
| Total Depreciation and Amortization | -92.28% | 235.71% | 184.71% | 140.78% | 127.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.23% | -64.88% | -67.62% | -40.10% | -9.45% |
| Change in Net Operating Assets | 27.30% | -1,102.45% | -331.73% | -1,042.98% | -17,317.65% |
| Cash from Operations | 72.92% | 59.65% | 34.29% | 13.12% | -3.27% |
| Capital Expenditure | -- | 82.00% | 83.64% | -391.67% | -136.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -84.76% | -28.80% | 14.14% | 13.88% |
| Cash from Investing | -100.17% | -84.75% | -28.65% | 13.91% | 13.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.49% | -- | -85.96% | -79.18% | 777.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | -- | -- | -- |
| Cash from Financing | -92.94% | -100.67% | -94.11% | -87.82% | 709.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -171.50% | -237.13% | -295.00% | -301.43% | 189.69% |